Chi KN - Search Results

1

A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.

Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E. Chi KN, et al. Clin Cancer Res. 2008 Feb 1;14(3):833-9. doi: 10.1158/1078-0432.CCR-07-1310. Clin Cancer Res. 2008. PMID: 18245546 Clinical Trial.

2

Carboplatin and vinblastine for the treatment of metastatic transitional cell carcinoma of the urothelial tract.

Al-Karim HA, Tan KE, Chi KN, Bryce CJ, Murray NR, Coppin C. Al-Karim HA, et al. Among authors: chi kn. Am J Clin Oncol. 2002 Oct;25(5):515-9. doi: 10.1097/00000421-200210000-00019. Am J Clin Oncol. 2002. PMID: 12393996

3

Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

Townsley CA, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason GA, Stewart D, Goel R, Ruether JD, Siu LL, Jolivet J, McIntosh L, Seymour L, Moore MJ; National Cancer Institute of Canada-Clinical Trials Group. Townsley CA, et al. J Clin Oncol. 2003 Apr 15;21(8):1524-9. doi: 10.1200/JCO.2003.03.057. J Clin Oncol. 2003. PMID: 12697876 Clinical Trial.

4

Antisense approaches in prostate cancer.

Chi KN, Gleave ME. Chi KN, et al. Expert Opin Biol Ther. 2004 Jun;4(6):927-36. doi: 10.1517/14712598.4.6.927. Expert Opin Biol Ther. 2004. PMID: 15174974 Review.

5

Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer.

Chi KN. Chi KN. World J Urol. 2005 Feb;23(1):33-7. doi: 10.1007/s00345-004-0477-x. Epub 2005 Feb 19. World J Urol. 2005. PMID: 15723221 Review.

6

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

Winquist E, Moore MJ, Chi KN, Ernst DS, Hirte H, North S, Powers J, Walsh W, Boucher T, Patton R, Seymour L. Winquist E, et al. Among authors: chi kn. Urol Oncol. 2005 May-Jun;23(3):143-9. doi: 10.1016/j.urolonc.2004.12.012. Urol Oncol. 2005. PMID: 15907712 Clinical Trial.

7

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.

Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME. Eigl BJ, et al. Among authors: chi kn. Clin Cancer Res. 2005 Jul 1;11(13):4905-11. doi: 10.1158/1078-0432.CCR-04-2140. Clin Cancer Res. 2005. PMID: 16000589 Free article.

8

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.

Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, Gelmon KA. Chi KN, et al. Invest New Drugs. 2005 Aug;23(4):311-5. doi: 10.1007/s10637-005-1439-x. Invest New Drugs. 2005. PMID: 16012790 Clinical Trial.

9

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. Chi KN, et al. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96. doi: 10.1093/jnci/dji252. J Natl Cancer Inst. 2005. PMID: 16145049 Clinical Trial.

10

Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers.

Gleave M, Chi KN. Gleave M, et al. Among authors: chi kn. Ann N Y Acad Sci. 2005 Nov;1058:1-15. doi: 10.1196/annals.1359.001. Ann N Y Acad Sci. 2005. PMID: 16394121 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

281 results

Search Page

Filters